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Abstract
Introduction: Light chain deposition disease (LCDD) can involve the heart and cause severe heart
failure. Cardiac involvement is usually described in the advanced stages of the disease. We report
the case of a woman in whom restrictive cardiomyopathy due to LCDD presented with paroxysmal
atrial fibrillation.
Case presentation: A 55-year-old woman was admitted to our emergency department because
of palpitations. In a recent blood test, serum creatinine was 1.4 mg/dl. She was found to have high
blood pressure, left ventricular hypertrophy and paroxysmal atrial fibrillation. An ACE-inhibitor
was prescribed but her renal function rapidly worsened and she was admitted to our nephrology
unit. On admission serum creatinine was 9.4 mg/dl, potassium 6.8 mmol/l, haemoglobin 7.7 g/dl, N-
terminal pro-brain natriuretic peptide 29894 pg/ml. A central venous catheter was inserted and
haemodialysis was started. She underwent a renal biopsy which showed kappa LCDD. Bone
marrow aspiration and bone biopsy demonstrated kappa light chain multiple myeloma.
Echocardiographic findings were consistent with restrictive cardiomyopathy. Thalidomide and
dexamethasone were prescribed, and a peritoneal catheter was inserted. Peritoneal dialysis has
now been performed for 15 months without complications.
Discussion: Despite the predominant tubular deposition of kappa light chain, in our patient the
first clinical manifestation of LCDD was cardiac disease manifesting as atrial fibrillation and the
correct diagnosis was delayed. The clinical management initially addressed the cardiovascular
symptoms without paying sufficient attention to the pre-existing slight increase in our patient's
serum creatinine. However cardiac involvement is a quite uncommon presentation of LCDD, and
this unusual case suggests that the onset of acute arrhythmias associated with restrictive
cardiomyopathy and impaired renal function might be related to LCDD.
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Introduction
Light chain deposition disease (LCCD) is a systemic dis-
ease involving several organs. Kidney impairment usually
dominates the clinical picture, and proteinuria and renal
failure are the most common clinical manifestations [1].
Heart involvement plays a crucial role in the prognosis of
the disease; signs and symptoms of cardiac dysfunction
are related to the degree of myocardial deposition of light
chains, and generally occur in the advanced stages of the
disease. We report a case of LCCD in which paroxysmal
atrial fibrillation was the first clinical manifestation.
Case presentation
In December 2006, a 55-year-old woman was admitted to
the emergency department of our hospital because of pal-
pitations. She had a history of cholecystectomy because of
biliary stone, hysterectomy and hypothyroidism treated
with thyroxine 50 µg/day. In a laboratory test performed
in October 2006, serum creatinine was 1.4 mg/dl and
urine analysis was normal. Clinical examination showed
hypertension and atrial fibrillation. Echocardiography
demonstrated left ventricular hypertrophy and diastolic
dysfunction, with normal ejection fraction. The atrial
fibrillation resolved spontaneously, and treatment with
an angiotensin converting enzyme (ACE)-inhibitor was
started. In January 2007, a further episode of atrial fibril-
lation occurred. It resolved after intravenous propaf-
enone, but serum laboratory tests showed an increase in
creatinine (3 mg/dl) and potassium levels (5.8 mmol/l),
and the ACE-inhibitor was stopped. Thyroid function was
normal. Three weeks later, serum creatinine was found to
have further increased up to 5 mg/dl, whereas both kid-
neys appeared normal on sonography (US) examination.
The patient was admitted to our nephrology unit. On
admission serum creatinine was 9.4 mg/dl (normal refer-
ence values 0.7–1.3), potassium 6.8 mmol/l (normal ref-
erence values 3.7–5.3), and haemoglobin 7.7 g/dl
(normal reference values 11.5–16.5). Two units of packed
red cells were transfused, a central venous catheter was
inserted, and haemodialysis was started. Proteinuria was 1
g/day and urine sediment analysis showed haematuria.
Serum glucose was 85 mg/dl (normal reference values 70–
110), sodium 140 mmol/l (normal reference values 136–
146), calcium 2.4 mmol/l (normal reference values 2.15–
2.55), proteins 7.1 g/dl (normal reference values 6.6–8.7),
and albumin 43 g/L (normal reference values 35–46);
protein electrophoresis did not show any monoclonal
spike, IgG was 630 mg/dl (normal reference values 600–
1600), IgA 71 mg/dl (normal reference values 70–400),
IgM 44 mg/dl (normal reference values 40–230), C3 132
mg/dl (normal reference values 90–180), C4 54 mg/dl
(normal reference values 16–38), autoantibodies were
negative and N-terminal pro-brain natriuretic peptide
(NT-proBNP) was 29894 pg/ml (Roche, Indianapolis, IN,
USA; normal reference values <247 pg/ml). Immunofixa-
tion showed monoclonal kappa light chain in the urine.
Echocardiography detected substantial thickening of the
left wall in the septum and posterior wall and diastolic
ventricular dysfunction, findings suggestive of restrictive
cardiomyopathy.
The patient underwent US-guided biopsy of the lower
pole of the right kidney, and two specimens were
obtained for light and electron microscopy examination.
Light microscopy examination showed smooth and con-
tinuous deposition of eosinophil material in the tubular
basement membrane, mild thickening and stiffness of the
glomerular basement membrane, and increase of the
mesangial matrix. Congo red stain was negative, but
immunofluorescence revealed linear deposits of kappa
light chains within the tubular basement membranes.
Electron microscopy examination displayed coarse granu-
lar electron-dense deposits in the outer surface of the
tubular basement membranes (Figure 1), and nonfibrillar
electron dense material along the glomerular basement
membrane and in the mesangium (Figure 2). Bone mar-
row aspiration and bone biopsy were performed, and his-
tologic examination of the specimens confirmed the
diagnosis of monoclonal immunoglobulin deposition
disease associated to kappa light chain multiple myeloma.
Treatment with thalidomide 100 mg/day and dexametha-
sone 40 mg on days 1–4 every 28 days was started, a peri-
toneal catheter was inserted, and the patient was changed
from haemodialysis to peritoneal dialysis. At the time of
Electron microscopy photograph showing coarsely granular  electron-dense deposits along the outer surface of the tubu- lar basement membrane Figure 1
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writing the patient has been dialysing for 15 months and
no major complications have been recorded.
The study has been conducted according to the Declara-
tion of Helsinky.
Discussion
The pathogenesis of LCDD is similar to that of primary
amyloidosis. Both are monoclonal plasma cell prolifera-
tive disorders characterized by tissue deposition of light
chain fragments, leading to organ impairment. Myeloma
is diagnosed in about 40% of patients with LCDD [2]. In
LCDD light chain fragments do not form amyloid fibrils;
they are defined as non-amyloid immunoglobulin light
chains, and are mostly kappa chains. They cause renal fail-
ure and extra-renal manifestations usually secondary to
heart, liver and peripheral nerve involvement [3]. Survival
is quite variable, ranging from 1 month to 10 years from
the onset of symptoms, and mortality is mainly due to
heart or liver failure, or progression to multiple myeloma
[2]. Serum creatinine at the time of diagnostic renal
biopsy seems to be the only predictive factor of renal func-
tion and patient survival [1,3].
In plasma cell disorders with dysproteinemia, the aggrega-
tion of non-amyloid immunoglobulin light chains forms
granular deposits, diffusely distributed in systemic base-
ment membranes, which suggest a mechanism of aggrega-
tion and deposition different from primary amyloidosis
[4]. Several cofactors have been suggested to play a role in
promoting fibrilogenesis, such as the binding to subunit
proteins, the stabilization of fibrils, and their protection
from degradation [5]. In the kidneys, LCDD is often asso-
ciated with deposits in the tubular basement membranes
and Bowman's capsule, which may be more prominent
than those deposits seen in the glomeruli. Clinical presen-
tation depends in part on the site of deposition: it follows
that patients with predominant glomerular deposition
develop nephrotic syndrome, while those with predomi-
nant tubular deposition develop renal failure and mild
proteinuria [2]. In most cases, renal function declines rap-
idly, with the clinical features of subacute tubulointersti-
tial nephritis or rapidly progressive glomerulonephritis
[3]. In our patient, the clinical presentation showed simi-
lar characteristics, but it was initially misunderstood. An
ACE-inhibitor was prescribed without paying sufficient
attention to the slight increase in creatinine levels, and the
subsequent worsening of renal function was ascribed to
that medication. Such a misunderstanding delayed the
correct diagnosis, and the clinical management was erro-
neously focussed on the cardiac manifestations. Indeed,
atrial fibrillation associated with restrictive cardiomyopa-
thy is a quite uncommon presentation of LCDD, and the
patient was referred to the nephrology unit only when the
renal disease impairment became severe.
Endomyocardial biopsy is the gold standard to demon-
strate heart involvement in LCDD. Histologic examina-
tion of deep-frozen specimens shows amorphous Congo
red-negative deposits that are positive for light chains on
immunofluorescence [6,7]. Clinical manifestations of
heart involvement are variable and similar to those
observed in restrictive cardiomyopathy induced by amy-
loidosis. They can range from congestive heart failure to
arrhythmias and conduction disorders; myocardial infarc-
tion has also been reported [8,9]. Recently Toor et al. [10]
described cardiac nonamyloidotic immunoglobulin dep-
osition disease in 8 patients who underwent endomyocar-
dial biopsy. The median age was 49.5 years, none of them
were symptomatic and on echocardiography six patients
had concentric left ventricular hypertrophy with diastolic
dysfunction. One of them developed atrial fibrillation
during chemotherapy and responded to therapy with dig-
oxin.
In our patient left ventricular morphology and the trans-
mitral inflow pattern demonstrated by doppler echocardi-
ography were consistent with diastolic ventricular
dysfunction due to restrictive cardiomyopathy [11].
Response to treatment may differ between amyloidosis-
induced and LCDD-induced cardiomyopathy, and the lat-
ter could resolve after successful treatment of the underly-
ing plasma cell disorder [7]. However, whatever signs and
symptoms may reveal heart impairment in LCDD, they
usually occur in the advanced stages of the disease.
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To our knowledge, atrial fibrillation associated with
restrictive cardiomyopathy has never been previously
reported in the medical literature as a first clinical mani-
festation of restrictive cardiomyopathy due to LCDD.
Although Palladini et al. [12] demonstrated that NT-
proBNP assay can be useful in detecting cardiac involve-
ment in amyloidosis, we observed that natriuretic peptide
levels were no more effective than echocardiography in
evaluating heart disease in a patient with primary amy-
loidosis and uraemia [13]. However, the very high levels
of NT-proBNP observed in the patient in this present case
report could have been the result of the combination of
heart involvement and impaired renal function, as renal
failure can influence NT-proBNP assay performed by
Roche method [14].
In conclusion, this unusual case suggests that the onset of
acute arrhythmias associated with restrictive cardiomyop-
athy and impaired renal function might be related to
LCDD.
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